“…In the case of cetuximab, the cause was severe radiodermatitis (grade 3, 64%) combined with a grade 3 cetuximab‐related skin rash (24%). Mucosal toxicity and, possibly, some other side effects (eg, xerostomia, dysphagia) would be decreased with the implementation of intensity‐modulated radiation therapy and a more conformal dose distribution, which was not in routine use in our department at that time . Severe skin damage provoked by joint action of megavoltage X‐rays, CP, and cetuximab resulted in a pronounced hypopigmentation at sites of the most intensive dermal reaction within the RT field in 6 of our patients, which is usually not seen when RT is combined with only CP (Figure ).…”